Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Brno
Clinical trial register · Czechia

Clinical Trials in Brno, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Czechia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1522 matching records held by the registry are in this view. Synced 14 Nov 2026, 03:18 UTC
1522
Studies in scope
all four open statuses
785
Recruiting now
open to new participants
303
Lead sponsors
across recruiting studies
Top sites
Prague 34 Brno 20 Hradec Králové 19 Ostrava 15 Olomouc 9

Trials with a site in Brno

20 of 1522 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Czechia
Start
Recruiting
Sanofi
Phase 3
980
Brno, Hradec Králové
2025-10-08
Recruiting
Sanofi
Phase 3
980
Brno, Hradec Králové, Prague
2025-10-01
Active, closed
Sanofi
Phase 2
105
Brno, Slaný
2025-07-07
Recruiting
Sanofi
Phase 2
99
Brno, Hradec Králové, Slaný
2025-06-03
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
Sanofi
Phase 3
300
Brno, Prague
2025-04-01
Active, closed
Sanofi
Phase 2
229
Brno, Havířov, Klatovy, Prague
2024-08-29
Recruiting
Sanofi
Phase 3
160
Brno, Hradec Králové, Ostrava, Pardubice, Prague
2024-08-21
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
Sanofi
Phase 3
109
Brno, Hradec Králové, Pardubice
2024-07-12
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Sanofi
Phase 3
2,500
Brno, Hradec Králové, Jihlava, Ostrava - Poruba, Pardubice, Prague, Praha 5 - Motol, Teplice
2024-04-16
Active, closed
Sanofi
Phase 3
943
Brno, Hradec Králové, Jihlava, Ostrava, Prague, Teplice, Zlín
2023-12-27
Active, closed
Sanofi
Phase 3
1,655
Brno, Hradec Králové, Jihlava, Ostrava, Pardubice, Prague, Teplice, Zlín
2023-12-13
Active, closed
Sanofi
Phase 2/3
1,856
Brno, Kutná Hora, Nový Jičín, Olomouc, Ostrava, Pilsen, Prague
2022-08-22
Active, closed
Sanofi
Phase 3
531
Brno, Olomouc, Ostrava, Prague
2022-06-23
Active, closed
Sanofi
Phase 2
129
Brno, Hradec Králové, Jihlava, Ostrava - Poruba, Teplice
2021-06-07
Active, closed
Sanofi
Phase 3
337
Brno, Hradec Králové, Olomouc, Ostrava - Poruba, Prague
2020-06-16
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Czech investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 November 2026. https://priyalifescience.com/clinical-trials-czechia/city/brno

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Czechia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,522 studies in total at the last sync on 14 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies with a site in Brno that also match the filters currently applied.

How many clinical trials are recruiting in Brno?

5 of the 20 studies on this page are recruiting new participants as of the 14 Nov 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 13 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Brno), 20 studies
PhaseStudiesRecruitingShare
Phase 313465%
Phase 26130%
Phase 2/3105%

Most active sponsors

Lead sponsors with the most studies (Brno)
Lead sponsorStudiesRecruiting
Sanofi205
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.